Table 1.
Study Design HCV002
| Arm | Patients (n) | IFN/Rib | ChAd3 Prime (Week) | ChAd3 Second Prime (Week) | Ad6 Boost (Week) | Dose of All Vaccines | Follow‐Up (Months) |
|---|---|---|---|---|---|---|---|
| A1 | 3a | + | 14 | — | 24 | 5 × 108 vp | 18 |
| A2 | 2b | + | 14 | — | 24 | 5 × 109 vp | 18 |
| A3 | 6 | + | 14 | — | 24 | 2.5 × 1010 vp | 18 |
| A4 | 6 | + | 2 | — | 12 | 2.5 × 1010 vp | 18 |
| A5 | 4 | + | 14 | 18 | 28 | 2.5 × 1010 vp | 18 |
| A6 | 4 | + | 2 | 6 | 16 | 2.5 × 1010 vp | 18 |
| Patients receiving vaccination alone (no IFN/RIB) | |||||||
| B1 | 2 | ‐ | 4 | — | 14 | 5 × 108 vp | 9 |
| B2 | 2 | ‐ | 4 | — | 14 | 5 × 109 vp | 9 |
| B3 | 4 | ‐ | 4 | — | 14 | 2.5 × 1010 vp | 9 |
a
One volunteer received prime vaccine only and was replaced (021).
b
One volunteer in this arm received prime only (031).